B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice

References

• Sun X, Yu W, Hu C. Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. Biomed Res Int. 2014;2014:926713. doi:10.1155/2014/926713.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–26. doi:10.1038/nrendo.2017.151.
   PubMed Web of Science ®Google Scholar
• Edward Michieka O, Benjamin Moranga O. The rise of noncommunicable diseases in Kenya: an examination of the time trends and contribution of the changes in diet and physical inactivity. J Epidemiol Glob Health. 2018;8(1–2):1–7. doi:10.2991/j.jegh.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843.
   PubMed Web of Science ®Google Scholar
• Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Med. 2017;130(6):S4–S17. doi:10.1016/j.amjmed.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Whang A, Nagpal R, Yadav H. Bi-directional drug-microbiome interactions of anti-diabetics. EBioMedicine. 2019;39:591–602. doi:10.1016/j.ebiom.2018.11.046
   PubMed Web of Science ®Google Scholar
• Horii T, Iwasawa M, Kabeya Y, Atuda K. Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: a Japanese database analysis. Sci Rep. 2019;9(1):12992. doi:10.1038/s41598-019-49424-2.
   PubMedGoogle Scholar
• Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858. doi:10.1038/nm.4345.
   PubMed Web of Science ®Google Scholar
• Liao X, Song L, Zeng B, Liu B, Qiu Y, Qu H, Zheng Y, Long M, Zhou H, Wang Y. et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EBioMedicine. 2019;44:665–674. doi:10.1016/j.ebiom.2019.03.057.
   PubMed Web of Science ®Google Scholar
• Chan CW, Yu C-L, Lin J-C, Hsieh Y-C, Lin C-C, Hung C-Y, Li C-H, Liao Y-C, Lo C-P, Huang J-L. et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018;17(1):20. doi:10.1186/s12933-018-0663-6.
   PubMedGoogle Scholar
• Tomas J, Mulet C, Saffarian A, Cavin J-B, Ducroc R, Regnault B, Kun Tan C, Duszka K, Burcelin R, Wahli W. et al. High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine. Proc Natl Acad Sci USA. 2016;113(40):E5934–e5943. doi:10.1073/pnas.1612559113.
   PubMed Web of Science ®Google Scholar
• Xavier-Santos D, Bedani R, Lima ED, Saad SMI. Impact of probiotics and prebiotics targeting metabolic syndrome. J Funct Foods. 2020;64:103666. doi:10.1016/j.jff.2019.103666
   Web of Science ®Google Scholar
• Mazziotta C, Tognon M, Martini F, Torreggiani E, Rotondo JC. Probiotics mechanism of action on immune cells and beneficial effects on human health. Cells. 2023;12(1):184. doi:10.3390/cells12010184.
   PubMed Web of Science ®Google Scholar
• Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Moghari A. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94(7):3288–3294. doi:10.3168/jds.2010-4128.
   PubMed Web of Science ®Google Scholar
• Qian X, Si Q, Lin G, Zhu M, Lu J, Zhang H, Wang G, Chen W. Bifidobacterium adolescentis is effective in relieving type 2 diabetes and May Be related to its dominant core genome and gut microbiota modulation capacity. Nutrients. 2022;14(12):2479. doi:10.3390/nu14122479.
   PubMed Web of Science ®Google Scholar
• Yan F, Li N, Shi J, Li H, Yue Y, Jiao W, Wang N, Song Y, Huo G, Li B. et al. Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice. Food Funct. 2019;10(9):5804–5815. doi:10.1039/C9FO01062A.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Scarlata GGM, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B, Roncada P, Luzza F. Metabolic- Dysfunction-Associated Fatty liver disease and gut microbiota: from Fatty liver to dysmetabolic syndrome. Med (Kaunas). 2023;59(3):594. doi:10.3390/medicina59030594.
   PubMed Web of Science ®Google Scholar
• Yan X, Feng B, Li P, Tang Z, Wang L. Microflora disturbance during progression of glucose intolerance and effect of Sitagliptin: an animal study. J Diabetes Res. 2016;2016:2093171. doi:10.1155/2016/2093171.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, Wang N, Lu Y. A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front Endocrinol. 2018;9. doi:10.3389/fendo.2018.00233.
   Web of Science ®Google Scholar
• Pryor R, Martinez-Martinez D, Quintaneiro L, Cabreiro F. The role of the microbiome in drug response. Annu Rev Pharmacol Toxicol. 2020;60(1):417–435. doi:10.1146/annurev-pharmtox-010919-023612.
   PubMedGoogle Scholar
• Wang D, Liu J, Zhong L, Ding L, Zhang Q, Yu M, Li M, Xiao X. Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice. Front Pharmacol. 2022;13:1004617. doi:10.3389/fphar.2022.1004617.
   PubMed Web of Science ®Google Scholar
• Koh A, Mannerås-Holm L, Yunn N-O, Nilsson PM, Ryu SH, Molinaro A, Perkins R, Smith JG, Bäckhed F. Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylation. Cell Metab. 2020;32(4):643–653.e644. doi:10.1016/j.cmet.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, Kanno R, Tamura Y, Asahara T, Takahashi T. et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep. 2017;7(1):12115. doi:10.1038/s41598-017-12535-9.
   PubMedGoogle Scholar
• Kocsis T, Molnár B, Németh D, Hegyi P, Szakács Z, Bálint A, Garami A, Soós A, Márta K, Solymár M. et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta- analysis of randomized clinical trials. Sci Rep. 2020;10(1):11787. doi:10.1038/s41598-020-68440-1.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S. et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015. doi:10.1038/s41467-020-18414-8.
   PubMed Web of Science ®Google Scholar
• Gai Z, Liao W, Huang Y, Dong Y, Feng H, Han M. Effects of bifidobacterium BL21 and lacticaseibacillus LRa05 on gut microbiota in type 2 diabetes mellitus mice. AMB Express. 2023;13(1):97. doi:10.1186/s13568-023-01603-1.
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Rossignol P, Bakris G, Mehta C, White WB, Zannad F. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021;20(1):187. doi:10.1186/s12933-021-01382-8.
   PubMedGoogle Scholar
• Choi H-M, Kim HR, Kim E-K, Byun YS, Won Y-S, Yoon W-K, Kim H-C, Kang J-G, Nam K-H. An age-dependent alteration of the respiratory exchange ratio in the db/db mouse. Lar. 2015;31(1):1–6. doi:10.5625/lar.2015.31.1.1.
   Google Scholar
• Ko KY, Wu YW, Liu CW, Cheng MF, Yen RF, Yang WS. Longitudinal evaluation of myocardial glucose metabolism and contractile function in obese type 2 diabetic db/db mice using small-animal dynamic (18)F-FDG PET and echocardiography. Oncotarget. 2017;8(50):87795–87808. doi:10.18632/oncotarget.21202.
   PubMedGoogle Scholar
• Suriano F, Vieira-Silva S, Falony G, Roumain M, Paquot A, Pelicaen R, Régnier M, Delzenne NM, Raes J, Muccioli GG. et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021;9(1):147. doi:10.1186/s40168-021-01097-8.
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Kahn SE. The role of Insulin Resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753–4761. doi:10.1210/jc.2006-0587.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14(3–4):222–231. doi:10.2119/2007-00119.Tilg.
   PubMed Web of Science ®Google Scholar
• Rehman K, Akash MSH. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016;23(1):87. doi:10.1186/s12929-016-0303-y.
   PubMed Web of Science ®Google Scholar
• Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017;9(4):387. doi:10.3390/nu9040387.
   PubMed Web of Science ®Google Scholar
• Sargent J. IL-22 and metabolic disease. Nat Rev Endocrinol. 2014;10(11):639–639. doi:10.1038/nrendo.2014.148.
   PubMed Web of Science ®Google Scholar
• Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J. et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514(7521):237–241. doi:10.1038/nature13564.
   PubMed Web of Science ®Google Scholar
• Chen H, Sun L, Feng L, Yin Y, Zhang W. Role of innate lymphoid cells in obesity and insulin resistance. Front Endocrinol. 2022;13. doi:10.3389/fendo.2022.855197.
   Web of Science ®Google Scholar
• Kalyesubula M, Mopuri R, Rosov A, Alon T, Edery N, Moallem U, Dvir H. Hyperglycemia-stimulating diet induces liver steatosis in sheep. Sci Rep. 2020;10(1):12189. doi:10.1038/s41598-020-68909-z.
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler AC, Barak O, Elazar M. et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. 2018;359(6382):1376–1383. doi:10.1126/science.aar3318.
   PubMed Web of Science ®Google Scholar
• Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196. doi:10.1155/2020/3920196.
   PubMed Web of Science ®Google Scholar
• Sharma BR, Jaiswal S, Ravindra PV. Modulation of gut microbiota by bioactive compounds for prevention and management of type 2 diabetes. Biomed Pharmacother. 2022;152:113148. doi:10.1016/j.biopha.2022.113148
   PubMed Web of Science ®Google Scholar
• Jayashree B, Bibin YS, Prabhu D, Shanthirani CS, Gokulakrishnan K, Lakshmi BS, Mohan V, Balasubramanyam M. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014;388(1–2):203–210. doi:10.1007/s11010-013-1911-4.
   PubMed Web of Science ®Google Scholar
• Sakura T, Morioka T, Shioi A, Kakutani Y, Miki Y, Yamazaki Y, Motoyama K, Mori K, Fukumoto S, Shoji T. et al. Lipopolysaccharide-binding protein is associated with arterial stiffness in patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2017;16(1):62. doi:10.1186/s12933-017-0545-3.
   PubMedGoogle Scholar
• Khondkaryan L, Margaryan S, Poghosyan D, Manukyan G. Impaired inflammatory response to LPS in type 2 diabetes mellitus. Int J Inflam. 2018;2018:2157434. doi:10.1155/2018/2157434.
   PubMedGoogle Scholar
• Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites. 2021;11(3):155. doi:10.3390/metabo11030155.
   PubMed Web of Science ®Google Scholar
• Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770. doi:10.1016/j.metabol.2021.154770.
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc Health Risk Manag. 2007;3(2):203–210. doi:10.2147/vhrm.2007.3.2.203.
   PubMedGoogle Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z.
   PubMed Web of Science ®Google Scholar
• Shen J, Fang Y, Zhu H, Ge W. Plasma interleukin-22 levels are associated with prediabetes and type 2 diabetes in the Han Chinese population. J Diabetes Investig. 2018;9(1):33–38. doi:10.1111/jdi.12640.
   PubMed Web of Science ®Google Scholar
• Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. J Intern Med. 2019;286(1):32–40. doi:10.1111/joim.12892.
   PubMed Web of Science ®Google Scholar
• Gong F, Wu J, Zhou P, Zhang M, Liu J, Liu Y, Lu X, Liu Z. Interleukin-22 might act as a double-edged sword in type 2 diabetes and coronary artery disease. Mediators Inflamm. 2016;2016:8254797. doi:10.1155/2016/8254797.
   PubMed Web of Science ®Google Scholar
• Zai W, Chen W, Liu H, Ju D. Therapeutic opportunities of IL-22 in Non-Alcoholic Fatty liver disease: from molecular mechanisms to clinical applications. Biomedicines. 2021;9(12):1912. doi:10.3390/biomedicines9121912.
   PubMed Web of Science ®Google Scholar
• Chen W, Zai W, Fan J, Zhang X, Zeng X, Luan J, Wang Y, Shen Y, Wang Z, Dai S. et al. Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury. Theranostics. 2020;10(13):5879–5894. doi:10.7150/thno.43894.
   PubMed Web of Science ®Google Scholar
• Abadpour S, Halvorsen B, Sahraoui A, Korsgren O, Aukrust P, Scholz H. Interleukin-22 reverses human islet dysfunction and apoptosis triggered by hyperglycemia and LIGHT. J Mol Endocrinol. 2018;60(3):171–183. doi:10.1530/jme-17-0182.
   PubMed Web of Science ®Google Scholar
• Ma Q, Luan J, Bai Y, Xu C, Liu F, Chen B, Ju D, Xu H. Interleukin-22 in renal protection and its pathological role in kidney diseases. Front Immunol. 2022;13:851818. doi:10.3389/fimmu.2022.851818.
   PubMed Web of Science ®Google Scholar
• Gulhane M, Murray L, Lourie R, Tong H, Sheng YH, Wang R, Kang A, Schreiber V, Wong KY, Magor G. et al. High fat diets induce colonic epithelial cell stress and inflammation that is reversed by IL- 22. Sci Rep. 2016;6(1):28990. doi:10.1038/srep28990.
   PubMedGoogle Scholar
• Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, Sun J, Pan F, Zhou J, Zhang W. et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020;11(1):4457. doi:10.1038/s41467-020-18262-6.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Stephens JW, Harris DA. Intestinal microbiota and their metabolic contribution to type 2 diabetes and obesity. J Diabetes Metab Disord. 2021;20(2):1855–1870. doi:10.1007/s40200-021-00858-4.
   PubMed Web of Science ®Google Scholar
• Tang R, Li L. Modulation of short-chain fatty acids as potential therapy method for type 2 diabetes mellitus. Can J Infect Dis Med Microbiol. 2021;2021:6632266. doi:10.1155/2021/9756586.
   PubMed Web of Science ®Google Scholar
• Chun E, Lavoie S, Fonseca-Pereira D, Bae S, Michaud M, Hoveyda HR, Fraser GL, Gallini Comeau CA, Glickman JN, Fuller MH. et al. Metabolite-sensing receptor Ffar2 regulates colonic group 3 Innate Lymphoid Cells and gut immunity. Immunity. 2019;51(5):871–884.e876. doi:10.1016/j.immuni.2019.09.014.
   PubMed Web of Science ®Google Scholar
• Sivaprakasam S, Prasad PD, Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol Ther. 2016;164:144–151. doi:10.1016/j.pharmthera.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Yin X, Wang G, Elinav E, Hao L, Zhao L, Flavell RA. IL-22 Deficiency Alters Colonic Microbiota To Be Transmissible and Colitogenic. J Immunol. 2013;190(10):5306–5312. doi:10.4049/jimmunol.1300016.
   PubMed Web of Science ®Google Scholar
• Peralta G, Sánchez MB, Roiz MP, Garrido JC, Teira R, Mateos F. Diabetes does not affect outcome in patients with Enterobacteriaceae bacteremia. BMC Infect Dis. 2009;9(1):94. doi:10.1186/1471-2334-9-94.
   PubMedGoogle Scholar
• Chen YR, Jing QL, Chen FL, Zheng H, Chen LD, Yang ZC. Desulfovibrio is not always associated with adverse health effects in the Guangdong gut microbiome project. PeerJ. 2021;9:e12033. doi:10.7717/peerj.12033
   PubMed Web of Science ®Google Scholar
• Kaur H, Bose C, Mande SS. Tryptophan metabolism by gut microbiome and gut-Brain-Axis: an in silico analysis. Front Neurosci. 2019;13. doi:10.3389/fnins.2019.01365.
   Web of Science ®Google Scholar
• Almugadam BS, Ibrahim MK, Liu Y, Chen SM, Wang CH, Shao CY, Ren BW, Tang L. Association of urogenital and intestinal parasitic infections with type 2 diabetes individuals: a comparative study. BMC Infect Dis. 2021;21(1):20. doi:10.1186/s12879-020-05629-9.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Funasaka Y, Saeki H, Yamamoto M, Kanda N. Dietary Fiber Inulin Improves Murine Imiquimod- Induced Psoriasis-like Dermatitis. Int J Mol Sci. 2023;24(18):14197. https://www.mdpi.com/1422-0067/24/18/14197.
   PubMed Web of Science ®Google Scholar
• Su X, Zhang M, Qi H, Gao Y, Yang Y, Yun H, Zhang Q, Yang X, Zhang Y, He J. et al. Gut microbiota–derived metabolite 3-idoleacetic acid together with LPS induces IL-35+ B cell generation. Microbiome. 2022;10(1):13. doi:10.1186/s40168-021-01205-8.
   PubMed Web of Science ®Google Scholar
• Dupraz L, Magniez A, Rolhion N, Richard ML, Da Costa G, Touch S, Mayeur C, Planchais J, Agus A, Danne C. et al. Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal γδ T cells. Cell Rep. 2021;36(1):109332. doi:10.1016/j.celrep.2021.109332.
   PubMed Web of Science ®Google Scholar
• WJ RR K, Doo EH, Choi YK, Kim KH, Kim BK, Kim BK, Kim H, Kim M, Huh CS. Supplementation with the probiotic strains Bifidobacterium longum and lactiplantibacillus rhamnosus alleviates glucose intolerance by restoring the IL-22 response and pancreatic beta cell dysfunction in type 2 diabetic mice. Probiotics Antimicrob Proteins. 2023. doi:10.1007/s12602-023-10156-5.
   Web of Science ®Google Scholar
• Song I, Patel O, Himpe E, Muller CJ, Bouwens L, Rooman I. Beta cell Mass restoration in alloxan-diabetic mice treated with EGF and Gastrin. PLoS One. 2015;10(10):e0140148. doi:10.1371/journal.pone.0140148.
   PubMed Web of Science ®Google Scholar
• Kwon EY, Kim SY, Choi MS. Luteolin-enriched artichoke leaf extract alleviates the metabolic syndrome in mice with high-fat diet-induced obesity. Nutrients. 2018;10(8):979. doi:10.3390/nu10080979.
   PubMed Web of Science ®Google Scholar
• Yao B, Dong T, Fu A, Li H, Jiang C, Li N, Cai S. Quantification and characterization of mouse and human tissue- resident microbiota by qPCR and 16S sequencing. STAR Protoc. 2022;3(4):101765. doi:10.1016/j.xpro.2022.101765.
   PubMedGoogle Scholar
• Illumina. 16S Metagenomic Sequencing Library Preparation_Preparing 16S ribosomal RNA gene amplicons for the Illumina MiSeq system. https://support.illumina.com/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf.
   Google Scholar
• Wang H, Song W, Wu Q, Gao X, Li J, Tan C, Zhou H, Zhu J, He Y, Yin J. et al. Fecal transplantation from db/db mice treated with sodium butyrate attenuates ischemic stroke injury. Microbiol Spectr. 2021;9(2):e0004221. doi:10.1128/Spectrum.00042-21.
   PubMed Web of Science ®Google Scholar